Rossari Biotech Q2 Profit Rises as Saudi Expansion Proceeds

Consolidated net profit reached Rs 389.07 million for Q2 FY27.
Revenue grew to Rs 6,975.60 million for the quarter ending September 30, 2026.

Reader Takeaway: Steady year-on-year profit growth alongside strategic international expansion in Saudi Arabia signals long-term capacity building for shareholders.

What just happened

Rossari Biotech Limited announced its financial results for the quarter and half-year ended September 30, 2026. The company posted consolidated revenue of Rs 6,975.60 million compared to Rs 5,861.07 million in the year-ago period. Net profit increased to Rs 389.07 million from Rs 368.76 million. Standalone results also showed growth, with revenue rising to Rs 4,952.76 million and net profit reaching Rs 342.31 million.

Why this matters

The financial performance indicates sustained operational growth. Crucially, the Board has formally approved the leasing of land for a new greenfield manufacturing facility in Saudi Arabia through its subsidiary, Rossari International Limited Company. This development, previously hinted at in January 2026, represents a significant move to enhance global production capabilities.

What changes now

Following the board's land leasing approval, the company will finalize project details and capital expenditure requirements. These plans are expected to be presented to the board in coming meetings. Additionally, the company processed the allotment of 2,500 equity shares under its 2019 Employee Stock Option Plan.

What to track next

Investors should monitor future filings for specific capital outlay figures regarding the Saudi Arabian project and updates on the project's construction timeline, as these will directly influence future cash flows and balance sheet commitments.